Purpose Because the occurrence of postoperative myocardial ischaemia (MI) predicts subsequent cardiac morbidity and mortality, we determined the prevalence of and risk factors for MI in hip and knee arthroplasty patients. Methods High-sensitivity cardiac troponin T (hs-cTnT) was measured on stored samples from postoperative day two in 394 hip and knee arthroplasty patients≥65 years of age enrolled in the Genetics-InFormatics Trial (GIFT). Results Fifty-three (13.5 %) participants had MI, of whom only three were diagnosed clinically during their hospitalisation. The risk of MI increased with age [odds ratio (OR) 3.52 per decade, 95 % confidence interval (CI) 2.00-6.19] and diabetes (OR 2.23, 95 % CI 1.04-4.77). MI was rarer with statins (OR 0.74, 95 % CI 0.40-1.35) and more common with hypertension, coronary artery disease and tobacco use, although these were not statistically significant. Conclusions Subclinical MI occurs frequently after arthroplasty. Diabetic and elderly patients are at highest risk.
Introduction
With the aging of the American population and the increased prevalence of obesity, > one million Americans undergo hip or knee arthroplasty each year for osteoarthritis [1] . Based on the National Hospital Discharge database, 1.1 % of arthroplasty patients are diagnosed with cardiac complications in the 90 days after surgery [2] . However, most orthopaedic surgery patients with myocardial ischaemia (MI) do not complain of angina. For example, in a study of 200 hip fracture participants, 71 (35 %) had an elevated troponin level but only 8 % of them complained of chest pain [3] . Therefore, the overall incidence of postoperative MI in orthopaedic patients is likely much higher than 1.1 %.
Understanding the true incidence and risk factors for postoperative MI in orthopaedic patients is important for several reasons. Firstly, the occurrence of even asymptomatic postoperative MI predicts subsequent cardiac morbidity and mortality [4] [5] [6] [7] [8] [9] [10] . Secondly, understanding the risk of postoperative MI can help patients make an informed decision about undergoing arthroplasty. Third, identifying patients at elevated cardiac risk can spur preemptive actions, such as giving cardioprotective medications peri-operatively to those that need them. For example, perioperative beta-adrenergic receptor blockers decrease the risk of postoperative ischaemia although they increase the risk of postoperative ischemic stroke [11] . Likewise, peri-operative aspirin therapy may decrease the risk of postoperative myocardial infarction, cardiac arrest, severe arrhythmia, pulmonary embolism and cardiovascular-related death but can cause major bleeding [12] [13] [14] . Three (3)-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) reduce the rate of myocardial infarction by 43-53 % after some noncardiac surgeries, even when started only one to 30 days before surgery [15] [16] [17] , but their benefit in orthopaedic surgery patients is unknown.
This study was performed in order to quantify the incidence of and risk factors for postoperative MI in orthopaedic patients. We conducted a cohort study nested within a multicentre trial of pharmacogenetic vs. clinical dosing of warfarin therapy in individuals undergoing elective hip or knee arthroplasty. We used a fourth-generation, high-sensitivity cardiac troponin T (hs-cTnT) assay to detect postoperative MI.
Materials and methods
Participants were recruited for an ancillary study to the Genetics InFormatics Trial (GIFT) of Warfarin Therapy to Prevent DVT (NHLBI R01 HL097036). As previously described [18] , GIFT is an ongoing multi-centre randomised trial that uses Web-based warfarin-dosing algorithms (www.WarfarinDosing.org) in individuals ≥ 65 years of age undergoing hip or knee arthroplasty.
Plasma samples were obtained from consenting GIFT study patients on postoperative day two, which were then frozen and stored. Batch testing for hs-cTnT was performed at a later date on deidentified samples. Measurement of hscTnT was accomplished in the General Core Laboratory of the Weill Cornell Medical College Clinical and Translational Science Center using a quantitative sandwich enzyme immunoassay kit from Meso Scale Discovery (MSD), Catalog Number K151EFC-1 (Gaithersburg, MD, USA) and processed using the MULTI-ARRAY Human Cardiac Troponin T MSD assay following the manufacturer's instructions. The assay had a lower level of detection of 13 ng/L and a coefficient of variation (COVA) of 7 %. This assay has 100 % cross-reactivity with troponin. In this study, MI was defined as an hs-cTnT level≥14 ng/L, the published 99th percentile cutoff for this assay [9] . Deidentified patient demographics and medical history were obtained from the GIFT study database; demographics were analysed descriptively.
Statistical analysis
Logistic regression was performed to determine which factors were associated with a higher risk of MI. We offered the following variables in the backwards stepwise regression model: age, total hip vs. knee arthroplasty, bilateral vs. unilateral total knee arthroplasty, body mass index, coronary artery disease, creatinine clearance, diabetes, hypertension, race, sex, smoker status, use of a statin and history of stroke. A p value of 0.5 was used to retain variables in the model, and a two-sided p value≤ 0.05 was required to determine statistical significance.
To further quantify the odds ratio (OR) of MI in participants prescribed a statin, we used an inverse probability treatment of weighting propensity score (IPTW). The IPTW used the following covariates: age, sex, race, diabetes, coronary artery disease, smoker status, blood pressure, and bilateral arthroplasty (see Appendix). A propensity score is the conditional probability of treatment assignment given the observed baseline characteristics. Propensity score conditioning results in unbiased estimates of the average treatment effect [19] . The Shapiro-Wilk test and normal probability plots were used to confirm normality. Chi-square goodness-of-fit test was used to compare unadjusted and IPTW-adjusted baseline characteristics. Hosmer and Lemeshow goodness-of-fit test determined model fit. The IPTW resulted in a cstatistic of 0.66. Statistical data were calculated with SAS, version 9.2 (SAS Institute Inc., Cary, NC, USA). This study was performed in accordance with ethical 
Results
Postoperative day two (POD2) plasma samples were available for hs-cTnT measurement from 394 hip or knee arthroplasty patients. Two hundred and ninetynine (76 %) of these individuals underwent total knee arthroplasty, including 40 (10 %) who underwent bilateral knee arthroplasty. The average [standard deviation (SD)] age of patients was 71.8 (6.2) years (Table 1) .
Fifty-three patients (13.5 %) had MI postoperatively (hs-cTnT≥14 ng/L) (Fig. 1) . The proportion of patients with MI did not differ by site. Only three participants (0.77 %) were identified clinically as having MI during their hospital stay. These participants had POD2 hscTnT levels of 32.7, 34.1 and 35.6, respectively. The risk of MI increased with age (OR) 3.52 per decade, 95 % confidence interval (CI) 2.00-6.19) and diabetes (OR 2.23, 95 % CI 1.04-4.77). Myocardial ischaemia was less common with a statin (OR 0.74, 95 % CI 0.40-1.35) and more common with hypertension, coronary artery disease and tobacco use, although these were not statistically significant.
After using a propensity score to adjust for the likelihood of being on a statin and performing nonparsimonious stepwise regression, only age and diabetes mellitus were significant predictors of postoperative MI: the odds increased 3.5-fold per decade of life and 2.2-fold in participants with diabetes mellitus (Table 2) . Although not statistically significant, the odds of MI were lower in participants on statin therapy and higher in participants with hypertension and coronary artery disease, smokers and those undergoing bilateral knee arthroplasty ( Table 2) .
Discussion
More than one million Americans undergo hip or knee arthroplasty each year [1] , and 1-2 % are reported to experience arterial thrombotic complications, such as CAD coronary artery disease, TKA total knee arthroplasty acute stroke, myocardial infarction or vascular-related death [2, [20] [21] [22] . Using a high-sensitivity assay to measure hs-cTnT, we found evidence of MI in 13.5 % of patients after hip or knee arthroplasty. Of note, only 0.77 % of patients were diagnosed clinically with MI (on the basis of symptoms and troponin measurement) during their hospital stay. The frequency of clinically apparent MI noted in our study was similar to the published 0.2-0.7 % rate of postarthroplasty myocardial infarction derived from administrative data [22] [23] [24] [25] . Clinical detection of MI in the postoperative setting is difficult, because patients and clinicians are focused on musculoskeletal pain, and opiates used for orthopaedic pain can mask angina. We found that many patients with undetected ischaemia are discharged without potentially beneficial therapies, such as beta antagonists, aspirin, angiotensin-converting enzyme inhibitors and/or statins.
Fourth-generation hs-cTnT assays are highly specific for MI [26] . Although elevated levels can be seen in critically ill patients [9, 27] , patients in this study were clinically well. Fourth-generation hs-cTnT assays have greater sensitivity to detect MI than traditional assays [26, 28, 29] . In VISION, for example, a study of 15, 133 patients >45 years undergoing noncardiac surgery, 11.6 % were found to have MI postoperatively. Even low levels of ischaemia were clinically important in VI-SION: postoperative hs-cTnT values as low as 20 ng/L or 30 ng/L predicted 30-day mortality [10] . Nagele et al. also found that peri-operative hs-cTnT elevations presaged mortality [9] . Hietala et al. demonstrated that peri-operative troponin elevation in hip-fracture patients was associated with both higher short-term (17 vs 4.7 %, p = 0.008) and long-term (61 vs 40 %, p = 0.005) mortality rates [30] . There were no deaths in our study, but this was most likely due to the small number of patients analysed (n=394).
The risk of MI in our study was higher with advancing age and in patients with diabetes, suggesting that these patients may benefit from cardiac monitoring and troponin testing postoperatively. Ischemia also tended to be more common among patients who had other risk factors for MI (hypertension, CAD, smoking, bilateral TKA, male sex, and African American race).
Our finding that diabetes is a significant risk factor for silent ischaemia confirms prior studies. For example, in a study of 579 individuals undergoing sestamibi stress tests, there was a higher incidence of silent ischaemia among diabetic patients [31] . Similarly, in a study of nearly 2000 patients without a history of known myocardial infarction diagnosis, diabetes was an independent predictor of silent myocardial infarction (OR 1.5, 95 % CI 1.1-1.9, p =0.004) [32] .
Our finding that silent ischaemia is more common in the elderly also is supported by the literature. For example, in a population-based cohort study of 5888 participants≥65 years of age without a history of a myocardial infarction, 15.3 % of participants had evidence of myocardial infarction by baseline electrocardiogram (ECG) studies, 22.3 % of which had been unrecognised [33] . Prior studies in orthopaedic patients have also demonstrated an association between advanced age and MI. In a study of patients undergoing hip-fracture surgery, 44.4 % of those ≥ 90 years of age experienced troponin elevations, compared with 12.5 % of participants<70 years of age (p<0.01) [3] .
Our study was limited by insufficient sample size to quantify the effects of statin use on MI. In addition, because ECG testing was not routinely performed, we do not know whether patients with elevated hs-cTnT levels had accompanying ECG changes. Highsensitivity cTnT levels were only available from POD2 plasma samples. Although troponin is known to be elevated for seven to ten days, we could not record hscTnT levels serially, as many patients were discharged within the first three days, and we lacked funding to do so. We also lacked baseline hs-cTnT levels, which have also been shown to predict adverse outcomes [9] . These limitations are balanced by strengths, including complete follow-up for all 394 participants and standardised warfarin management (based on the GIFT study protocol).
In contemporary studies, postoperative myocardial infarction occurs at rates similar to those of pulmonary embolism following hip and knee arthroplasty [2, 23-25, 34, 35] . The results of our study suggest that patients at high risk for ischaemia, such as diabetics and the elderly, may benefit from postoperative troponin testing. Safe new approaches to cardioprotection are also needed. Given that statin therapy has been shown to reduce the risk of adverse cardiovascular outcomes after a variety of high-risk surgeries [15] [16] [17] 36] , we propose a randomised trial of statins vs. placebo in patients aged≥65 years undergoing orthopaedic surgery. 
